ArticleBMC infectious diseases2026
Evaluation of measles immunity in the central black sea region of Türkiye.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEradication of the measles virus is a major requirement to promote global health. Great progress has been made in reducing the incidence of measles through vaccination efforts. In our study, we aimed to determine the levels of immunity against measles in our region and to examine the relationship between age groups and gender.
methodsThe results of patients admitted to our hospital, a tertiary care hospital located in the Central Black Sea Region in the north of Türkiye, between May 2021 and December 2024 were retrospectively analyzed. Serum samples were tested for measles-specific IgG and IgM antibodies using the LIAISON® Measles IgG and IgM (DiaSorin, Italy) chemiluminescence immunoassay (CLIA).
resultsA total of 5252 individuals aged ≥ 4 years were included in the study, of whom 3423 (65.2%) were female and 1829 (34.8%) were male. Overall, 70.7% of participants were seropositive for measles IgG antibodies. Measles IgG seropositivity was found in 69.5% of women and 73.0% of men; the difference between genders was statistically significant (p = 0.007). Seropositivity rates increased significantly with advancing age, ranging from 60.8% in individuals aged 4–30 years to 97.5% in those aged ≥ 41 years (p < 0.05).
conclusionIdentifying non-immune individuals remains an important component of measles elimination strategies. In this study, individuals aged 4–30 years exhibited lower measles IgG seropositivity compared with older age groups, suggesting a potential immunity gap in this population. Higher immunity levels observed in older age groups were consistent with differences in birth cohorts and historical measles vaccination policies. Future research evaluating the durability of vaccine-induced immunity and the potential role of additional immunization strategies may help inform evidence-based vaccination policies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.